An observational study in Rheumatoid Arthritis, sponsored by Fraunhofer Institute for Translational Medicine and Pharmacology ITMP. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by Fraunhofer Institute for Translational Medicine and Pharmacology ITMP · Observational
Non-interventional, prospective, observational study to assess the relative risk of anti-CCP positive patients to develop (subclinical) signs of inflammation in accordance with early Rheumatoid Arthritis (RA) in a population without pre-classified RA but new1 onset of non-specific musculoskeletal (MSK) symptoms in general practices in Germany and subsequent 36 months follow-up by rheumatologists
Studies of early arthritis cohorts have shown that a large number of early arthritis patients cannot be accurately diagnosed at their first visit, and hence are often referred as undifferentiated arthritis patients. If patients are found to be anti-CCP(+) when referred to the clinician, however, more than 90% develop RA within 3 years - in contrast to only 30% of the anti-CCP(-) patients. The presence of anti-CCP antibodies in undifferentiated arthritis therefore accurately predicts development of RA. Anti-CCP antibodies are very specific for RA, and they are produced at significant level very early in disease. The specificity of anti-CCP antibodies for the diagnosis of RA is high (94.1-99.0%). Moreover, it has been reported that anti-CCP antibodies can be present many years before the first visit to the clinic (up to 18 years). Furthermore, the presence of anti-CCP antibodies at the first visit to the clinician predicts radiographic progression, as demonstrated by many studies that have shown a strong association of anti-CCP positivity with the development of bone erosions.Early diagnosis of RA coupled with rational use of disease-modifying anti-rheumatic drugs (DMARD) has been shown to have a favourable effect on the course of the disease. Early and accurate diagnosis has therefore become increasingly important. Implementing anti-CCP quick tests in general practices could facilitate an early detection of RA or the allocation to a high risk RA group. This, in turn, would guarantee an early referral of the patient to a rheumatologist and together with other clinical examinations can aid in the early diagnosis and treatment. As has been shown in many studies an early intervention is vital to preserve joint function and to improve patient care. In this study, we want to assess the relative risk for patients derived from GPs in Germany with new onset of non-specific MSK symptoms and anti-CCP test positivity to develop (subclinical) signs of inflammation in accordance with early RA. Those patients will be identified in general practices and will be tested for anti-CCP status. Anti-CCP positive patients will then be introduced to a rheumatologist to validate anti-CCP status and examine presence of clinical signs of early RA in addition to subclinical signs of MSK inflammation. Furthermore, to focus on the possibility of early detection of anti-CCP before the onset of clinically active arthritis, patients will be followed-up by a rheumatologist until detection of early RA or up to 36 months in total. Early RA will be examined using standard of care for signs of inflammation including clinical examination for swollen and tender joints. In addition, ultrasound will be performed to assess joint inflammation as well as fluorescence optical imaging technique (Xiralite®) to sensitively illustrate changes in microvascularisation as a marker of subclinical inflammation. In cases of RA diagnosis, the study ends with the date of diagnosis and patients will receive treatment according to local guidelines earlier and medical care will be continued in clinical routine care conditions outside of the study. Moreover, the cooperation status between GPs and rheumatologists will be evaluated using qualitative interviews. Feasibility of the diagnosis of early RA in at risk patients as well as the feasibility of the transferral of these patients from the general practice to the rheumatologist will be assessed. Training of GPs for detection of early RA will be improved. Overall, the hypothesis of the study is that patients with new onset of unspecific MSK-symptoms and who are positive for anti-CCP, which both are risk factors for developing RA, will be earlier introduced to and monitored by a rheumatologist for proper clinical examination and potential treatment when establishing RA, which in turn will not only improve patient care, disease outcomes and quality of life, but might also be cost effective.
2,963 studies on the registry are indexed under Arthritis, Rheumatoid; 396 are open to participants now.
This study's enrollment of 986 is above the median of 176 across 854 observational studies indexed under Arthritis, Rheumatoid.
Browse Arthritis, Rheumatoid studies →This is the only study on the registry with Fraunhofer Institute for Translational Medicine and Pharmacology ITMP as lead sponsor.
Counted across the registry records on this site, refreshed daily.
population without pre-classified RA but new onset of non-specific musculoskeletal (MSK) symptoms
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis no intervention is given
Other: no intervention is given
Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
Other: no intervention is given
no intervention is given
Determination of the relative risk in patients with new onset of non-specific MSK symptoms who are anti-CCP positive to develop (subclinical) signs of inflammation in accordance with early RA in general practices in Germany
Determination if RA symptoms are present
Time frame: every 6 months up to 3 years
diagnosis of RA in the group of anti-CCP positive patients with new onset of non-specific MSK symptoms
Time frame: every 6 months up to 3 years
subclinical signs of inflammation using routine examination methods in anti-CCP positive patients
Time frame: every 6 months up to 3 years
subclinical signs of inflammation using fluorescence optical imaging technique in anti-CCP positive patients
Time frame: every 6 months up to 3 years
subclinical signs of inflammation using ultrasound in anti-CCP positive patients
Time frame: every 6 months up to 3 years
anti-CCP level over time in anti-CCP positive patients
Time frame: over 3 years
EQ5D
Questionnaire to assess Quality of Life profile of anti-CCP positive patients
Time frame: every 6 months up to 3 years
SF36
Questionnaire to assess Quality of Life profile of anti-CCP positive patients
Time frame: every 6 months up to 3 years
HAQ
Questionnaire to assess disability profile of anti-CCP positive patients
Time frame: every 6 months up to 3 years
PHQ-9
Questionnaire to assess depression profile of anti-CCP positive patients
Time frame: every 6 months up to 3 years
WPAI
Questionnaire to assess work ability profile of anti-CCP positive patients
Time frame: every 6 months up to 3 years
assessment of time to disease in anti-CCP positive patients
Time frame: every 6 months up to 3 years
assessment of correlation of anti-CCP level in anti-CCP positive patients
Time frame: every 6 months up to 3 years
assessment quality of life (QoL) in anti-CCP positive patients
Time frame: every 6 months up to 3 years
assessment work ability profile in anti-CCP positive patients
Time frame: every 6 months up to 3 years
assessment subclinical signs of inflammation in anti-CCP positive patients
Time frame: every 6 months up to 3 years
assessment risk of depression in anti-CCP positive patients
Time frame: every 6 months up to 3 years
assessment of grade of disability in anti-CCP positive patients
Time frame: every 6 months up to 3 years
diagnosis of RA in the group of ELISA test anti-CCP negative patients with new onset of non-specific MSK symptoms
Time frame: 1 year
diagnosis of RA in the group of ELISA test anti-CCP negative patients with new onset of non-specific MSK symptoms
Time frame: 3 years
diagnosis of RA in the group of quick test anti-CCP negative patients with new onset of non-specific MSK symptoms
Time frame: 1 year
Qualitative assessment of general practitioners' (GP) routine care
qualitative interviews with the GP to evaluate current status of how patients with MSK symptoms are treated/forwarded in general practices
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2017 to primary completion in Dec 2021, 55 months.
Of 196 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 96. This study's 55 months is above that.
Counting every sponsor, half of 317 studies reached it within 47 months; a quarter within 24 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.